scholarly journals MODERN METHODS OF DIAGNOSTIC IMAGING OF GLIOMAS

2019 ◽  
pp. 15-23
Author(s):  
N. A. Kostenikov ◽  
A. V. Pozdnyakov ◽  
V. F. Dubrovskaya ◽  
O. Yu. Mirolyubova ◽  
Yu. R. Ilyushchenko ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Magnetic Resonance ◽  
Diagnostic Imaging ◽  
Single Photon ◽  
Malignant Tumors ◽  
Photon Emission ◽  
Pathological Process ◽  
Emission Computed Tomography ◽  
Resonance Spectroscopy ◽  
Positron Emission

The review presents an analysis of the literature on the diagnosis of gliomas and the study of their structural and biological features based on implementation of new techniques in clinical practice of diagnostic imaging. These techniques include perfusion technologies for multislice spiral computed tomography (MSCT), magnetic resonance imaging (MRI), functional MRI, proton magnetic resonance spectroscopy (MRS), single photon emission computed tomography (SPECT), and positron emission tomography (PET) with various radiopharmaceuticals (RPHs), first and foremost, labeled amino acids, such as11C-L-methionine and18F-Fluoroethyltyrosine. There is presented that with the application of these two methods (MRI and PET), the most important biochemical processes underlying oncogenesis of malignant tumors might be studied by non-invasive way. The obtained data can be crucial for an early detection of tumor lesions, staging the pathological process, rationale for therapeutic tactics, personalization of treatment, evaluation of the efficiency of therapy at early stages and prognosis of the disease result.

scholarly journals Biomarkers in development of psychotropic drugs

2011 ◽  
Vol 13 (2) ◽  
pp. 225-234 ◽  
Keyword(s):  
Computed Tomography ◽  
Magnetic Resonance ◽  
Clinical Course ◽  
Single Photon ◽  
Imaging Techniques ◽  
Photon Emission ◽  
Cranial Computed Tomography ◽  
Emission Computed Tomography ◽  
Resonance Spectroscopy ◽  
Onset Of Action

Biomarkers have been receiving increasing attention, especially in the field of psychiatry In contrast to the availability of potent therapeutic tools including pharmacotherapy, psychotherapy, and biological therapies, unmet needs remain in terms of onset of action, stability of response, and further improvement of the clinical course. Biomarkers are objectively measured characteristics which serve as indicators of the causes of illnesses, their clinical course, and modification by treatment. There exist a variety of markers: laboratory markers which comprise the determination of genetic and epigenetic markers, neurotransmitters, hormones, cytokines, neuropeptides, enzymes, and others as single measures; electrophysiological markers which usually comprise electroencephalography (EEG) measures, and in particular sleep EEG and evoked potentials, magnetic encephalography, electrocardiogram, facial electromyography, skin conductance, and others; brain imaging techniques such as cranial computed tomography, magnetic resonance imaging, functional MRI, magnetic resonance spectroscopy, positron emission tomography, and single photon emission computed tomography; and behavioral approaches such as cue exposure and challenge tests which can be used to induce especially emotional processes in anxiety and depression. Examples for each of these domains are provided in this review. With a view to developing more individually tailored therapeutic strategies, the characterization of patients and the courses of different types of treatment will become even more important in the future.

The Role of Neuroimaging in the Diagnosis and Treatment of Depressive Disorder: A Recent Review

2018 ◽  
Vol 24 (22) ◽  
pp. 2515-2523 ◽  
Author(s):  
Tianbin Song ◽  
Xiaowei Han ◽  
Lei Du ◽  
Jing Che ◽  
Jing Liu ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Depressive Disorder ◽  
Diffusion Tensor ◽  
Single Photon ◽  
Rapid Development ◽  
Photon Emission ◽  
Clinical Manifestations ◽  
Brain Network ◽  
Emission Computed Tomography ◽  
Resonance Spectroscopy

Depression is a mental disorder with serious negative health outcomes. Its main clinical manifestations are depressed mood, slow thinking, loss of interest, and lack of energy. The rising incidence of depression has a major impact on patients and their families and imposes a substantial burden on society. With the rapid development of imaging technology in recent years, researchers have studied depression from different perspectives, including molecular, functional, and structural imaging. Many studies have revealed changes in structure, function, and metabolism in various brain regions in patients with depressive disorder. In this review, we summarize relevant studies of depression, including investigations using structural magnetic resonance imaging (MRI), functional MRI (task-state fMRI and resting-state fMRI), diffusion tensor imaging (DTI), magnetic resonance spectroscopy (MRS), brain network and molecular imaging (positron emission tomography [PET] and single photon emission computed tomography [SPECT]), which have contributed to our understanding of the etiology, neuropathology, and pathogenesis of depressive disorder.

scholarly journals A Nordic survey of CT doses in hybrid PET/CT and SPECT/CT examinations

2019 ◽  
Vol 6 (1) ◽  
Author(s):  
Natalie A. Bebbington ◽  
Bryan T. Haddock ◽  
Henrik Bertilsson ◽  
Eero Hippeläinen ◽  
Ellen M. Husby ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Single Photon ◽  
Photon Emission ◽  
Emission Computed Tomography ◽  
Single Photon Emission ◽  
Positron Emission ◽  
Pet Ct ◽  
Clinical Purpose ◽  
Single Photon Emission Computed ◽  
Photon Emission Computed Tomography

Abstract Background Computed tomography (CT) scans are routinely performed in positron emission tomography (PET) and single photon emission computed tomography (SPECT) examinations globally, yet few surveys have been conducted to gather national diagnostic reference level (NDRL) data for CT radiation doses in positron emission tomography/computed tomography (PET/CT) and single photon emission computed tomography/computed tomography (SPECT/CT). In this first Nordic-wide study of CT doses in hybrid imaging, Nordic NDRL CT doses are suggested for PET/CT and SPECT/CT examinations specific to the clinical purpose of CT, and the scope for optimisation is evaluated. Data on hybrid imaging CT exposures and clinical purpose of CT were gathered for 5 PET/CT and 8 SPECT/CT examinations via designed booklet. For each included dataset for a given facility and scanner type, the computed tomography dose index by volume (CTDIvol) and dose length product (DLP) was interpolated for a 75-kg person (referred to as CTDIvol,75kg and DLP75kg). Suggested NDRL (75th percentile) and achievable doses (50th percentile) were determined for CTDIvol,75kg and DLP75kg according to clinical purpose of CT. Differences in maximum and minimum doses (derived for a 75-kg patient) between facilities were also calculated for each examination and clinical purpose. Results Data were processed from 83 scanners from 43 facilities. Data were sufficient to suggest Nordic NDRL CT doses for the following: PET/CT oncology (localisation/characterisation, 15 systems); infection/inflammation (localisation/characterisation, 13 systems); brain (attenuation correction (AC) only, 11 systems); cardiac PET/CT and SPECT/CT (AC only, 30 systems); SPECT/CT lung (localisation/characterisation, 12 systems); bone (localisation/characterisation, 30 systems); and parathyroid (localisation/characterisation, 13 systems). Great variations in dose were seen for all aforementioned examinations. Greatest differences in DLP75kg for each examination, specific to clinical purpose, were as follows: SPECT/CT lung AC only (27.4); PET/CT and SPECT/CT cardiac AC only (19.6); infection/inflammation AC only (18.1); PET/CT brain localisation/characterisation (16.8); SPECT/CT bone localisation/characterisation (10.0); PET/CT oncology AC only (9.0); and SPECT/CT parathyroid localisation/characterisation (7.8). Conclusions Suggested Nordic NDRL CT doses are presented according to clinical purpose of CT for PET/CT oncology, infection/inflammation, brain, PET/CT and SPECT/CT cardiac, and SPECT/CT lung, bone, and parathyroid. The large variation in doses suggests great scope for optimisation in all 8 examinations.

Neuroimaging and the Origin of Psychiatric Symptoms in Dementia

1997 ◽  
Vol 8 (S3) ◽  
pp. 239-243 ◽  
Author(s):  
David L. Sultzer
Keyword(s):  
Computed Tomography ◽  
Density Functional ◽  
Psychiatric Symptoms ◽  
Functional Neuroimaging ◽  
Single Photon ◽  
Photon Emission ◽  
Emission Computed Tomography ◽  
Positron Emission ◽  
Single Photon Emission Computed ◽  
Photon Emission Computed Tomography

Neuroimaging studies have contributed greatly to our understanding of Alzheimer's disease and other dementias. Computed tomography and magnetic resonance imaging reveal brain structure and aid in the diagnostic evaluation of patients with cognitive impairment. Functional neuroimaging studies use positron emission tomography, single-photon emission computed tomography, and other methods to measure regional cerebral activity, including metabolic rate, blood flow, and neuroreceptor density. Functional neuroimaging results can be useful clinically and have also been used in a variety of research applications to examine physiologic variables in neuropsychiatric illnesses.

Sign in / Sign up

Export Citation Format

Share Document